Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.

Li S, Thangapazham RL, Wang JA, Rajesh S, Kao TC, Sperling L, Moss J, Darling TN.

Nat Commun. 2011;2:235. doi: 10.1038/ncomms1236.

2.

Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.

Li S, Takeuchi F, Wang JA, Fan Q, Komurasaki T, Billings EM, Pacheco-Rodriguez G, Moss J, Darling TN.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3539-44. doi: 10.1073/pnas.0712397105. Epub 2008 Feb 21.

3.

Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.

Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DF, Gallacher J, Sampson JR, Shen MH.

Oncogene. 2015 Feb 12;34(7):922-31. doi: 10.1038/onc.2014.17. Epub 2014 Mar 17.

PMID:
24632604
4.

A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles.

Pollizzi K, Malinowska-Kolodziej I, Doughty C, Betz C, Ma J, Goto J, Kwiatkowski DJ.

Hum Mol Genet. 2009 Jul 1;18(13):2378-87. doi: 10.1093/hmg/ddp176. Epub 2009 Apr 8.

5.

MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.

Li S, Takeuchi F, Wang JA, Fuller C, Pacheco-Rodriguez G, Moss J, Darling TN.

J Exp Med. 2005 Sep 5;202(5):617-24. Epub 2005 Aug 29.

6.

Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.

Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ.

Am J Respir Cell Mol Biol. 2010 Feb;42(2):227-34. doi: 10.1165/rcmb.2009-0050OC. Epub 2009 Apr 24.

7.
8.

Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).

Crowell B, Lee GH, Nikolaeva I, Dal Pozzo V, D'Arcangelo G.

eNeuro. 2015 Oct 22;2(6). pii: ENEURO.0046-15.2015. doi: 10.1523/ENEURO.0046-15.2015. eCollection 2015 Nov-Dec.

9.
10.

Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.

Campos T, Ziehe J, Fuentes-Villalobos F, Riquelme O, Peña D, Troncoso R, Lavandero S, Morin V, Pincheira R, Castro AF.

Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1200-7. doi: 10.1016/j.bbamcr.2016.03.009. Epub 2016 Mar 11.

11.

Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Babcock JT, Nguyen HB, He Y, Hendricks JW, Wek RC, Quilliam LA.

J Biol Chem. 2013 May 31;288(22):15687-98. doi: 10.1074/jbc.M112.431056. Epub 2013 Apr 23.

12.

Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.

Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke SP, Bajenaru ML, Onda H, Kwiatkowski D, Gutmann DH.

Oncogene. 2002 Jun 6;21(25):4050-9.

13.

Establishment of Tsc2‑deficient rat embryonic stem cells.

Ito Y, Kawano H, Kanai F, Nakamura E, Tada N, Takai S, Horie S, Arai H, Kobayashi T, Hino O.

Int J Oncol. 2015 May;46(5):1944-52. doi: 10.3892/ijo.2015.2913. Epub 2015 Mar 3.

PMID:
25738543
15.

High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

Medvetz D, Sun Y, Li C, Khabibullin D, Balan M, Parkhitko A, Priolo C, Asara JM, Pal S, Yu J, Henske EP.

Mol Cancer Res. 2015 Jan;13(1):50-62. doi: 10.1158/1541-7786.MCR-14-0440. Epub 2014 Sep 3.

16.

Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.

Yasuda S, Sugiura H, Katsurabayashi S, Shimada T, Tanaka H, Takasaki K, Iwasaki K, Kobayashi T, Hino O, Yamagata K.

Sci Rep. 2014 Jun 3;4:5155. doi: 10.1038/srep05155.

17.

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1.

Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD.

Mol Cell. 2012 Aug 24;47(4):535-46. doi: 10.1016/j.molcel.2012.06.009. Epub 2012 Jul 12.

18.

Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.

Malhowski AJ, Hira H, Bashiruddin S, Warburton R, Goto J, Robert B, Kwiatkowski DJ, Finlay GA.

Hum Mol Genet. 2011 Apr 1;20(7):1290-305. doi: 10.1093/hmg/ddq570. Epub 2011 Jan 6.

19.

Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.

Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP.

Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.

20.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

Supplemental Content

Support Center